Skip to main content
Triangle logo TriangleGet started

5hmC Biomarker (NCT07060001)

Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker: a one-minute explainerNCT070600011 min

5hmC Biomarker trial for Acute Myeloid Leukemia (AML) (NCT07060001). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with newly diagnosed, de novo acute myeloid leukemia.

The idea: use blood-DNA 5hmC patterns to assess residual leukemia and guide later treatment. Patients receive azacitidine or decitabine, which alter DNA methylation, with or without venetoclax, or intensive cytarabine plus an anthracycline. After four weeks, positive tests may lead to continued or changed treatment; negative tests lead to consolidation, possibly transplantation. Researchers compare residual disease, remission duration and survival.

This phase 2 study plans 112 patients. Shilpan Shah leads Houston Methodist’s recruiting Houston site.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.